Royalty Pharma plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Royalty Pharma plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.38B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $2.26B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $2.35B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $2.24B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $2.29B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $2.12B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $1.81B | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $1.79B | Feb 24, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $770.95M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $858.98M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $1.13B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $42.83M | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $619.73M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $975.04M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $2.35B | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $1.38B | Feb 24, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.56B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $1.29B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $1.49B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $307.07M | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $1.43B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $1.60B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $2.62B | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $1.36B | Feb 24, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $452.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $2.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $52.00M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $177.11M | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $200.08M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $26.29M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $83.04M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $392.61M | Feb 24, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.49B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $2.77B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $2.99B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $2.14B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $2.02B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $2.03B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $1.67B | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $1.62B | Feb 24, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.62B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $18.22B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $16.38B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $16.81B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $17.52B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $16.02B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $12.45B | Feb 24, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.91B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $7.88B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $6.30B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $7.29B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $7.27B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $6.12B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $6.31B | Feb 24, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $924.63M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Feb 11, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.36B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $2.85B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $2.52B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $1.96B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $2.26B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $1.92B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $2.83B | Feb 24, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $618.70M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $929.03M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $477.01M | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $1.71B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.54B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $1.01B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $246.20M | Feb 24, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.95B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $7.61B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $6.14B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $7.12B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $7.10B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $5.82B | Feb 15, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Feb 15, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Feb 15, 2023 |